Clinical Trial Update: Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) [Phase 3]

View source ↗

Summary

Open-label Phase 3 study of droxidopa in neurogenic orthostatic hypotension has completed and results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dopamine Beta-hydroxylase Deficiency
• Multiple System Atrophy
• Neurogenic Orthostatic Hypotension
• Non-diabetic Autonomic Neuropathy

Drugs mentioned

• Droxidopa (Droxidopa)

Snippet

Sponsor: Chelsea Therapeutics | Conditions: Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy | Phase 3 | Status: COMPLETED | Results posted: 2014-05-16